These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 32379358)

  • 21. Outcome after a dose "de-intensification" strategy with anti-TNF drugs in patients with Crohn's disease.
    Chaparro M; Barreiro-de Acosta M; García-Planella E; Domènech E; Bermejo F; Calvet X; Martín Arranz MD; Monfort D; Gisbert JP
    Gastroenterol Hepatol; 2016 Apr; 39(4):255-60. PubMed ID: 26620278
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of Infliximab in Crohn's Disease Patients with Prior Primary-Nonresponse to Tumor Necrosis Factor Antagonists.
    Clark-Snustad KD; Singla A; Lee SD
    Dig Dis Sci; 2019 Jul; 64(7):1952-1958. PubMed ID: 30815825
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective Evaluation of the Achievement of Mucosal Healing with Anti-TNF-α Therapy in a Paediatric Crohn's Disease Cohort.
    Nuti F; Civitelli F; Bloise S; Oliva S; Aloi M; Latorre G; Viola F; Cucchiara S
    J Crohns Colitis; 2016 Jan; 10(1):5-12. PubMed ID: 26188350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study.
    Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    J Crohns Colitis; 2014 Nov; 8(11):1454-63. PubMed ID: 24947334
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease.
    Singh S; Heien HC; Sangaralingham LR; Schilz SR; Kappelman MD; Shah ND; Loftus EV
    Clin Gastroenterol Hepatol; 2016 Aug; 14(8):1120-1129.e6. PubMed ID: 27058635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A virtual clinic increases anti-TNF dose intensification success via a treat-to-target approach compared with standard outpatient care in Crohn's disease.
    Srinivasan A; van Langenberg DR; Little RD; Sparrow MP; De Cruz P; Ward MG
    Aliment Pharmacol Ther; 2020 Jun; 51(12):1342-1352. PubMed ID: 32379358
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review.
    Billioud V; Sandborn WJ; Peyrin-Biroulet L
    Am J Gastroenterol; 2011 Apr; 106(4):674-84. PubMed ID: 21407178
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Anti-TNF therapy in treatment of luminal Crohn's disease].
    Marko B; Prka L
    Acta Med Croatica; 2013 Apr; 67(2):179-89. PubMed ID: 24471301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dose escalation of biologics in Crohn's disease: critical review of observational studies.
    Einarson TR; Bereza BG; Ying Lee X; Lelli F
    Curr Med Res Opin; 2017 Aug; 33(8):1433-1449. PubMed ID: 28537467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systematic review: efficacy of escalated maintenance anti-tumour necrosis factor therapy in Crohn's disease.
    Mattoo VY; Basnayake C; Connell WR; Ding N; Kamm MA; Lust M; Niewiadomski O; Thompson A; Wright EK
    Aliment Pharmacol Ther; 2021 Aug; 54(3):249-266. PubMed ID: 34153124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn's disease.
    Qiu Y; Chen BL; Mao R; Zhang SH; He Y; Zeng ZR; Ben-Horin S; Chen MH
    J Gastroenterol; 2017 May; 52(5):535-554. PubMed ID: 28275925
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. De-escalation of Biologic Treatment in Inflammatory Bowel Disease: A Comprehensive Review.
    Gisbert JP; Chaparro M
    J Crohns Colitis; 2024 Apr; 18(4):642-658. PubMed ID: 37943286
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.